In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• SARS-CoV-2 seroprevalence in <18 year olds (MMWR)
• EUA for T cell test (FDA)
• Lilly mAb bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-phase-3-trial-for-early-covid-19-301243984.html"> phase 3 results (Lilly)
• Biotechnology-and-GSK-Announce-VIR-7831-Reduces-Hospitalization-and-Risk-of-Death-in-Early-Treatment-of-Adults-with-COVID-19.html"> VIR-7831 mAb phase 3 results (Globenewswire)
• Molnupiravir phase 2a results (Merck)
• Ivermectin not supported for mild COVID-19 (JAMA)
• Recommendations for vaccinated-guidance.html"> fully vaccinated people (CDC)
• Letters read on TWiV 730
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv